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Abstract
Introduction 3,4-methylenedioxymethamphetamine
(MDMA) is known to improve psychomotor function and
mood when measured during daytime. However, MDMA
users tend to take this drug at dance parties while staying
awake for prolonged periods of time.
Subjects and methods This study was designed to assess
dose-related residual effects of MDMA on psychomotor
function and mood after a night without sleep. Sixteen
recreational MDMA users received single doses of 25, 50,
and 100 mg MDMA in a randomized, double-blind,
placebo-controlled cross-over study.
Results Results showed that sleep loss significantly impaired
psychomotor function. MDMA generally did not affect
performance but did improve rapid information processing
at the highest dose in the morning after administration. In the
evening, MDMA also increased subjective ratings of positive
mood at every dose and subjective arousal at the highest dose.
Thesesubjectiveeffectswerenolongerpresentafteranightof
sleep loss.
Discussion It is concluded that sleep deprivation impairs
psychomotor function and that stimulant effects of MDMA
are not sufficient to compensate for this impairment.
Keywords MDMA.Ecstasy.Psychomotor.Cognition.
Mood.Sleepdeprivation
Introduction
3,4-methylenedioxymethamphetamine (MDMA) is the
main psychoactive substance of the party drug ecstasy.
Ecstasy is a popular drug: about 0.4% of the Dutch general
population (40,000 people) has been described as current
user in 2005 (National Drug Monitor 2008) and 9.5 million
European adults indicated to have ever used ecstasy, which
is 2.8% of the general population (European Monitoring
Centre for Drugs and Drug Addiction 2008). Ecstasy has
been described as an entactogen, because of its subjective
effect of feeling close to and connected with others. Other
drug effects are enhanced visual and auditory perception:
colors appear brighter and sounds seem more intense. This
is why people generally take ecstasy at dance parties where
rhythmic music is being played in combination with
colorful lights. Also, the stimulant effects enable people to
dance for longer periods of time.
An extensive body of literature showed that ecstasy may
produce detrimental effects on cognitive and psychomotor
functions. For example, Morgan et al. (2006) found that
ecstasy users were impaired on several measures of
impulsivity compared to groups of polydrug users and
drug-naïve controls. Two meta-analytic reviews demon-
strated that ecstasy users performed significantly worse on
cognitive tasks measuring learning/memory, attention,
executive function, and psychomotor performance com-
pared to non-using control subjects, although effect sizes
were medium to small (Kalechstein et al. 2007; Zakzanis et
al. 2007). However, a large number of studies have also
failed to exclusively link MDMA use to long-term
cognitive impairments. Roiser et al. (2007) reported that
performance of current ecstasy users, former-ecstasy users,
polydrug users, and drug-naïve controls on tests measuring
memory, executive function, and impulsivity did not differ
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DOI 10.1007/s00213-009-1767-1between groups. Clark et al. (2009) reported no perfor-
mance difference between ecstasy users and controls on a
task that measured impulsivity. Hoshi et al. (2007) and
Hanson et al. (2008) concluded that the subtle impairments
of memory and impulse control in MDMA users were due
to polydrug use rather than ecstasy use alone. Likewise,
Lamers et al. (2006) and Jager et al. (2008) concluded that
impairments in cognitive and psychomotor function of
MDMA users may be attributed to other drugs than MDMA,
such as cannabis and amphetamine.
These conflicting findings of MDMA impairing perfor-
mance in some, but not all, studies have been attributed to
methodological problems inherent in cross-sectional
designs in abstinent drug users. For example, the fact that
most ecstasy users also take other drugs is an important
confounder. Thus, the results of the aforementioned studies
could be due to the use of other drugs than MDMA.
Another related problem is causality: the nature of cross-
sectional designs does not allow inferences on whether the
effects are caused by ecstasy or another factor, e.g.,
premorbid factors that might make people more vulnerable
to use illicit drugs (Morgan 2000).
One way to overcome these problems is to study acute
effects of MDMA on cognitive performance in placebo-
controlled experimental designs. In such designs, changes in
performance can be exclusively linked to the experimental
drug. Experimental studies have previously shown that single
doses of MDMA impair memory function (Dumont et al.
2008; Kuypers and Ramaekers 2005, 2007; Ramaekers et al.
2009) and attention (Dumont et al. 2008) and improve
performance on tasks measuring impulse control (Ramaekers
and Kuypers 2006) and psychomotor function (Lamers et al.
2003) when given during the day. The magnitude of
impairment on memory and attention increased when
MDMA was given during the night to subjects who stayed
awake throughout the night. Moreover, stimulating effects of
nocturnal doses of MDMA on psychomotor function,
vigilance, and sleepiness were very mild or no longer present
after a night of sleep loss (Kuypers et al. 2007, 2008). In the
latter studies, repeated doses of 75 and 50 mg MDMA
were administered to subjects, which resulted in psycho-
motor impairment additive to impairment produced by
sleep loss. However, MDMA also produced some mild
stimulatory effects; it reduced subjective feelings of
sleepiness and mildly increased vigilance performance in
the morning.
At present, it is not clear at which MDMA dose or serum
concentration residual impairments start to emerge. Residual
effects are limitedtothetimewindowinwhichthedrugisstill
present in blood, but at low concentrations. The objectives of
the present study were to establish the residual effects of
MDMA on cognitive performance early in the morning as a
function of MDMA dose. Subjects were treated on four
separate occasions with evening doses of 0, 25, 50, and
100 mg. Because identical MDMA doses can lead to different
MDMAbloodconcentrations,itisimportanttostudyMDMA
effects or it's interaction with sleep deprivation as a function
of MDMA concentrations rather than dose. We decided to
include a broad range of (low) nocturnal doses in order to be
able to measure residual MDMA effects at very low
concentrations in the morning. This wide range of residual
blood concentrations will help determine the MDMA
concentration threshold at which residual performance
effects will still be present. Performance was tested in the
evening, in the middle of the night, and in the morning after
a night of sleep loss.
Subjects and methods
Subjects
Eight males and eight females participated in this study.
Their mean (SE) age was 22.0 (0.41) years, and their mean
(SE) lifetime MDMA use was 27.0 (8.4) times. Subjects
were recruited by advertisements at Maastricht University
and were paid upon completion of the study. Before
enrollment, all subjects were screened by means of a
telephone interview to determine whether they qualified for
the study. The inclusion criteria were experience with
MDMA, i.e., at least one time in the last year; free from
psychotropic medication; good physical health as deter-
mined by a medical examination; absence of any major
medical, endocrine, and neurological condition; body mass
index between 18 and 28; and written informed consent.
The exclusion criteria were history of drug abuse or
addiction as assessed by means of a medical questionnaire
by the physician at the medical checkup; pregnancy or
lactation; cardiovascular abnormalities on electrocardio-
gram; excessive drinking, i.e., more than 20 alcoholic
consumptions a week; hypertension, i.e., systolic blood
pressure over 170 mmHg or diastolic blood pressure over
100 mmHg; and history of or current psychiatric disorder. If
subjects met the inclusion criteria, they received a medical
history and a drug questionnaire to get a more precise view
on their health and drug use. Finally, subjects underwent a
medical examination and took part in a training session to
get familiar with the tests.
This study was conducted according to the code of ethics
on human experimentation established by the declaration of
Helsinki (1964) and amended in Seoul (2008). Approval for
the study was obtained from the Medical Ethics committee
of the Academic Hospital of Maastricht and Maastricht
University. A permit for obtaining, storing, and administering
MDMA was obtained from the Dutch drug enforcement
administration.
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The study was conducted according to a double-blind,
placebo-controlled, randomized, four-way, cross-over design.
Treatments consisted of single doses of placebo, 25, 50, and
100 mg MDMA. Treatment orders were balanced over
subjects and treatment periods. Placebo and MDMA were
administered orally in identically appearing formulations.
MDMAwas dissolved in 25 mL bitter orange peel syrup, and
placebo consisted of only the bitter orange peel syrup. The
syrup was mixed with 200 mL juice before it was given to the
subjects. The wash-out period between treatments was at least
1w e e k .
Procedure
Subjects were asked to refrain from any drugs 1 week
before the medical examination until 2 weeks after study
completion. Subjects were not allowed to drink alcohol and
caffeine or smoke tobacco during a 24-h period prior to
testing. Subjects were always tested for alcohol and drugs,
i.e., tetrahydrocannabinol, opiates, amphetamine/ecstasy,
benzodiazepines, cocaine, and methamphetamine/ecstasy,
respectively, in breath and urine upon arrival (4:30 p.m.) at
the laboratory on test days. At 5:00 p.m. subjects received a
light, standard dinner, and at 5:15 p.m., MDMA or placebo
was administered. Performance was assessed in the evening,
the middle of the night, and in the morning after a night of
sleep loss. The timeline for performance testing, question-
naires, and blood draws are displayed in Fig. 1. Subjects
watched television or movies, played games, read a book or
magazine, or used the internet in between testing episodes
during a test night. An additional blood sample was drawn
1 week after each testing day to monitor renal and liver
function. A test day ended at 9:00 a.m. the next morning, at
which time, subjects were driven home.
Psychomotor assessment
The stop signal task required subjects to make quick key
responses to visually presented go signals and to inhibit
their response when a visual stop signal was suddenly
presented. The go signals were four 1.5 cm letters (A, B, C,
and D) presented one at a time in the center of a computer
screen. Subjects were required to respond to each letter as
quickly as possible by pressing one of two response
buttons. One button was pressed to indicate that A or C
appeared and the other to indicate B or D. Letters were
displayed for 500 ms, and the computer screen was blank
for 1.5 s inter-stimulus interval. This provided a period of
2 s in which the subject could respond to a letter. A single
test consisted of 176 trials in which each of the four-letter
stimuli was presented equally often. A stop signal occurred
in 48 trials during a test. The stop signal consisted of a
visual cue, i.e., *, that appeared in one of the four corners
of the screen. Stop signals were presented 12 times at each
of the four delays after the onset of a letter: 50, 150, 250,
and 350 ms. Trials always began with a 500-ms preparation
interval in which a fixation point appeared in the center of the
screen. The task lasted about 10 min. Dependent variables
were the proportion of commission errors on stop trials and
the reaction times (RT) on go as well as stop trials, i.e., stop
RT. Stop RT represents the estimated mean time required to
inhibit a response and is a measure of impulsivity (Fillmore et
al. 2002; Ramaekers and Kuypers 2006).
The rapid information-processing task is a self-paced
interactive working memory task that assessed subjects'
information-processing capacity. A pseudo-random sequence
of 250 digits (1–8) was presented in the center of the screen.
The digits were presented one at a time for 67 ms with an
initial inter-stimulus-interval (ISI) of 600 ms. Subjects had to
press a button when they saw the third digit of a three-digit
sequence (triad) that was comprised of even (e.g., 6, 2, and
4) and odd (e.g., 5, 1, and 7) digits. The entire 250-digit
sequence contained 11 even-digit triads and ten odd-digit
triads. Each correct response speeded up the presentation rate
by decreasing the ISI with 33 ms, and each false response
slowed it down with 33 ms. Task duration was 5 min; the
250-digit sequence was presented in a repeated loop. The
initial presentation rate of the test was 90 digits per minute,
and the dependent variable was the average number of digits
per minute presented in the test (Fillmore et al. 2005).
The divided attention task assessed the ability to divide
attention between two tasks performed simultaneously. The
Fig. 1 Timeline for blood samples, questionnaires, and laboratory tests relative to drug administration. GSS Groninger sleep scale, POMS profile
of mood states, TQ treatment questionnaire
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null the horizontal movement of a cursor from the center of
a display. The cursor traveled in both directions with
irregular velocity, but on average, 50% of what the subject
could just control. The dependent measures of this subtask
were control losses and tracking error, which was measured
by the absolute distance (millimeters) between the cursor's
position and the center. The secondary task involved
monitoring 24 single-digit numbers (0–9) that were
arranged in the four corners of the display. The numbers
changed asynchronously every 5 s. The requirement was to
react as rapidly as possible by lifting the foot from a pedal
every time a target, i.e., the number 2, appeared. Average
reaction time to targets was recorded as the dependent
measure (Moskowitz 1973).
The psychomotor vigilance task assessed the reaction
time in response to a visual stimulus. The visual stimulus
was a counter in the center of a computer screen that ran in
1 min from 0 to 60 with a fixed inter-stimulus interval of
1 ms. The counter started at random intervals between 2
and 10 s, and the subject had to react to the onset of the
counter as quickly as possible by pressing a response
button. Duration of the task was 10 min. This task has often
been used to assess the impact of sleep loss on performance
(Loh et al. 2004).
Subjective measures
The Groninger sleep scale assessed sleep quality and
quantity (hours of sleep). It consisted of 15 dichotomous
questions about sleep complaints and an open question
concerning the duration of sleep (Mulder-Hajonides van der
Meulen et al. 1980). The quality score ranged from 0 (best
quality of sleep) to 15 (worst quality of sleep).
The profile of mood states is a self-assessment mood
questionnaire with 72 five-point Likert scale items, represent-
ing eight mood states, i.e., anxiety, depression, anger, vigor,
fatigue, confusion, friendliness, and elation. Three composite
scales were derived, i.e., arousal ((anxiety+vigor)−(fatigue+
confusion)), positive mood (elation−depression), and a total
score((anxiety+depression+anger+fatigue)−vigor),whichis
a measure of malaise. The subject had to indicate to what
extent these items were representing his/her mood (de Wit et
al. 2002).
Pharmacokinetic assessment
Blood samples (8 mL) were collected two times throughout a
testing day/night, i.e., at 1.5 and 11 h post-drug. MDMA and
3,4-methylenedioxyamphetamine (MDA) concentrations were
determined afterwards in serum. The blood sample was
centrifuged immediately, and the resulting serum was frozen
at −20°C until analyses for pharmacokinetic assessments.
Statistical analyses
All statistical analyses were conducted by means of SPSS
16.0 for Mac. All data were entered in the general linear
model (GLM) repeated measures analysis of variance
(ANOVA) procedures with MDMA (four levels) and hours
of sleep loss (three levels) as main within-subject factors. If
the sphericity assumption was violated, the Greenhouse–
Geisser correction was used. In case of an overall effect of
MDMA or an interaction effect between MDMA and sleep
loss, separate drug-placebo contrast analyses were conducted
for each MDMA dose. In case of the profile of mood states,
difference scores between post-drug and the pre-drug score
entered the statistical analysis.
Results
Psychomotor assessment
Mean (SE) performance scores obtained from psychomotor
tests are displayed in Table 1 along with p values associated
with GLM ANOVA.
MDMA did not affect performance in any of the
psychomotor tasks. Sleep loss impaired performance on a
range of tasks. It increased RT (F2,30=6.415, p=0.005) and
stop RT (F2,30=3.685, p=0.037) in the stop signal task,
processing speed in the rapid information-processing task
(F2,30=7.896, p=0.002), and RT in the psychomotor
vigilance task (F2,30=16.598, p=0.000). Sleep loss also
increased control losses (F1.345,20.171=14.272, p=0.001),
tracking error (F2,30=16.449, p=0.000), and RT (F2,30=
35.538, p=0.000) in the divided attention task.
The interaction between MDMA and sleep loss was
significant for processing speed (F6,90=2.616, p=0.022) in
the rapid information-processing task. Simple drug-placebo
contrasts showed that this interaction effect was attributable
to MDMA 100 mg (p=0.001). Performance during the
placebo condition worsened during the night, while in the
100-mg MDMA condition, subjects' performance remained
stable throughout the night and slightly improved in the
morning (see Fig. 2).
Subjective measures
There were no significant differences in sleep quality and
quantity between any of the MDMA conditions as measured
by Groninger sleep scale. Subjects' mean (SE) quality of
sleep and hours of sleep were 2.22 (0.36) and 8.5 (0.24),
respectively.
ANOVA of the profile of mood states showed a
significant interaction between MDMA and sleep loss on
the arousal (F3,45=4.294, p=0.010) and positive mood scale
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indicated that MDMA 100 mg increased arousal (p=0.012)
in the evening but not in the morning, as compared to
placebo. Drug-placebo contrasts also showed that all MDMA
doses (p<0.046) increased positive mood in the evening
after drug intake but not in the morning. Mean (SE) arousal
and positive mood ratings during treatment are given in
Figs. 3 and 4,r e s p e c t i v e l y .
Pharmacokinetic assessment
Pharmacokinetic analysis in serum revealed mean (SE)
MDMA concentrations of 25.8 (3.3), 63.9 (6.4), and 157.2
(9.5) ng/mL at 1.5 h after administration of a 25-, 50-, and
100-mg dose, respectively. At 11.5 h post-drug, these
concentrations were 14.2 (2.7), 34.0 (3.9), and 84.3
Fig. 2 Mean (SE) performance on the rapid information-processing task
ineverytreatmentconditionasafunctionoftimeafterdrugadministration
Table 1 Mean (SE) of the cognitive and psychomotor tests for the treatment conditions and measuring times
Test Measure Placebo 25mg
MDMA
50mg
MDMA
100mg
MDMA
ANOVA
Sleep
deprivation
MDMA MDMA ×sleep
deprivation
Stop signal task
Commission errors (N) 1 4.8 (0.7) 4.5 (0.6) 5.1 (0.7) 5.3 (0.8)
2 5.5 (0.8) 3.0 (0.6) 4.5 (0.7) 4.8 (0.7) –– –
3 5.6 (0.7) 5.6 (0.6) 4.9 (0.6) 5.1 (0.7)
RT go (ms) 1 543 (36) 540 (23) 528 (25) 523 (23)
2 551 (35) 595 (30) 552 (27) 542 (28) 0.005 ––
3 555 (34) 585 (29) 562 (26) 578 (30)
Stop RT (ms) 1 276 (20) 271 (11) 292 (23) 315 (33)
2 327 (22) 290 (11) 279 (18) 299 (22) 0.037 ––
3 309 (25) 297 (16) 320 (33) 334 (23)
Rapid information processing
Processing speed (N/min) 1 529.0 (18.9) 525.2 (20.3) 506.0 (22.2) 522.1 (20.6)
2 519.4 (20.3) 511.8 (20.3) 496.1 (14.2) 517.3 (18.2) 0.002 – 0.022
3 468.0 (18.3) 462.9 (22.1) 479.9 (17.1) 526.4 (20.6)
Divided attention task
Control loss (N) 1 1.9 (0.7) 1.8 (0.5 2.9 (1.3) 1.6 (0.5)
2 12.6 (8.9) 14.4 (6.2) 5.6 (1.8) 6.1 (2.9) 0.001 ––
3 48.4 (12.3) 33.4 (7.2) 47.9 (14.3) 24.7 (5.7)
Tracking error (mm) 1 15.2 (1.1) 15.7 (1.2) 15.2 (1.0) 14.1 (1.2)
2 15.9 (1.3) 17.3 (1.1) 16.1 (1.2) 15.5 (1.3) 0.000 ––
3 19.3 (0.9) 19.7 (0.9) 18.0 (0.8) 18.5 (1.0)
RT (ms) 1 1,822 (63) 1,853 (79) 1,885 (74) 1,920 (70) 0.000 ––
2 2,046 (89) 2,013 (79) 2,017 (89) 1,973 (74)
3 2,180 (65) 2,189 (66) 2,246 (69) 2,285 (73)
Psychomotor vigilance task
RT (ms) 1 289 (8) 286 (8) 295 (15) 301 (13)
2 384 (47) 493 (108) 456 (76) 349 (26) 0.000 ––
3 464 (29) 463 (45) 544 (49) 515 (38)
Significance indicated by p value
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low to detect.
Discussion
The present study showed significant impairing effects of
sleep loss on various psychomotor measures. Performance
deteriorated without exception on all tasks as the hours of
sleep loss increased. RT in the stop signal, divided
attention, and psychomotor vigilance task as well as
processing speed in the rapid information-processing task
slowed down over time. Tracking error increased in the
divided attention task, which indicates that subjects were
unable to allocate sufficient cognitive resources to perform
the primary tracking task at a normal, placebo level, despite
a general slowing of RT in the secondary task. The number
of control losses increased dramatically in the morning after
sleep deprivation. Together, this shows that sleep deprivation
produced gross impairment of cognitive and psychomotor
functions. Similar findings have previously been reported by
Kuypers et al. (2007, 2008) and Dawson and Reid (1997).
The latter even demonstrated that performance decrements
for each hour of wakefulness between 10 and 26 h were
equivalent to a performance decrement observed with a
0.004% rise in blood alcohol concentration. According to
their model, performance of subjects in the present study after
17–24 h of sustained wakefulness would have decreased to a
level equivalent to the performance impairment observed at a
blood alcohol concentration of roughly 0.05–0.10%.
This study showed no main effects of MDMA on
performance, neither in the evening after drug administration
nor throughout the night. This contrasts somewhat with
findings of previous studies who reported neutral or even
stimulating effects on psychomotor function after single
doses of MDMA, particularly around Tmax (Kuypers et al.
2007; Lamers et al. 2003; Ramaekers and Kuypers 2006;
Ramaekers et al. 2006). It should be noted however that the
MDMA doses/concentrations in the present study were
relatively low compared to previous studies. This was
particularly true for MDMA concentrations early in the
morning. In the present study, the mean MDMA concentra-
tion in the 100-mg MDMA condition was 84.3 ng/mL at
11.5 h post-dosing. This concentration was about 2.5 times
lower than the concentration reported in a previous study
assessing the effect of repeated doses of MDMA on
psychomotor function after a night of sleep loss (Kuypers
et al. 2007, 2008).
The only significant interaction between MDMA and
sleep loss was caused by the highest dose of MDMA in the
present study. Relative to placebo, performance in the rapid
information-processing task slightly improved 14–15 h
after MDMA 100 mg, after a full night of sleep loss. This
interaction confirms some of the mild stimulatory character-
istics that have been reported before when measuring
MDMA effects at Tmax (Kuypers et al. 2006; Ramaekers
et al. 2006). In general, acute drug studies have shown that
MDMAeffectssubsideovertimeandnormalizeafterabout6h
after administration when taken during the day (Hernández-
López et al. 2002;D u m o n te ta l .2009). However, MDMA
effects on cognition may last longer or become more
noticeable when taken during the night or after a night
without sleep, because they may add to or even interact with
the detrimental effects of sleep loss on cognition. Kuypers et
al. (2007) demonstrated that nocturnal doses of MDMA
significant increased vigilance and decreased sleepiness in the
morning after a night of sleep loss. These results confirm the
residual, mild, stimulatory effects of MDMA on psychomotor
function that were measured in the present study after a
night of sleep loss. These data seem to indicate that mild
Fig. 4 Mean (SE) score on profile of moodstates positive mood scale in
every treatment condition as a function of time after drug administration
Fig. 3 Mean (SE) score on profile of mood states arousal scale in every
treatment condition as a function of time after drug administration
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the impairing effects of sleep loss on performance. However,
this effect of MDMA was very mild and only apparent in a
single performance task. Overall, MDMA did not compensate
for the detrimental effects of sleep loss on performance. This
conclusion is in line with work of others who also showed
that stimulant effects of MDMA are generally mild and not
sufficient to counteract the impairing effects of other sources
such as alcohol (Dumont et al. 2008; Kuypers et al. 2006).
The profile of mood states rating scales confirmed that
subjects actively experienced an MDMA effect even after
the lowest dose of 25 mg. Ratings of positive mood were
significantly elevated after all MDMA doses between 1 and
2 h after dosing. Likewise, feelings of arousal also
increased at Tmax, albeit only after the highest dose. These
positive feelings however did not last through the night.
W h e nr a t e di nt h em o r n i n gm o o da n da r o u s a lw e r e
considerable lower as compared to the evening before,
due to sleep loss, and not different from placebo. It again
shows that residual concentrations of MDMA or stimulatory
effects of MDMA on mood and arousal cannot compensate
for decrements in subjective mood and arousal as a result of
fatigue.
In summary, it can be concluded that sleep deprivation
has a major impairing effect on cognitive and psychomotor
performance. Low doses of MDMA generally failed to
affect performance but produced some stimulatory effect on
rapid information processing at the highest dose. MDMA
increased ratings of positive mood and alertness. However,
the stimulatory effects of MDMAwere only mild and never
sufficient to overcome decrements in performance, mood,
or arousal due to sleep loss.
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